Modest growth for Astellas in challenging quarter
This article was originally published in Scrip
Executive Summary
Astellasmight have warned about a tough year ahead at the time its year-end results were announced in May, but all things considered the company got off to a reasonable start in the first quarter, overcoming currency losses and the April price cut in Japan to post modest overall growth. But some new questions have appeared over the development of its Factor Xa inhibitor YM150.